Improvement of Vestibular Neuritis in a Patient with Psoriatic Arthritis following Ixekizumab Administration

Research output: Contribution to journalLetterpeer-review

Abstract

Psoriatic arthritis (PsA) is a chronic inflammatory condition commonly affecting peripheral joints and the skin. Recent studies have shown an association between PsA and vestibulocochlear dysfunction. Here, we present the case of a 43 year-old male with a history of controlled psoriasis (Pso) and PsA who presented with sudden-onset severe vertigo, nausea, and vomiting. Diagnostic evaluation ruled out a central etiology, leading to a diagnosis of vestibular neuritis of unknown origin. Despite minimal improvement with conventional medications, the patient experienced significant relief from vertigo symptoms following treatment with ixekizumab, an IL-17 inhibitor used to manage his PsA and Pso. This case highlights a potential therapeutic effect of biological agents on vestibular dysfunction associated with PsA. Future research in this area may provide insights into novel treatment strategies for vestibular symptoms in patients with PsA.

Original languageEnglish
Pages (from-to)1708-1710
Number of pages3
JournalSKIN: Journal of Cutaneous Medicine
Volume8
Issue number4
DOIs
StatePublished - Jul 2024

Fingerprint

Dive into the research topics of 'Improvement of Vestibular Neuritis in a Patient with Psoriatic Arthritis following Ixekizumab Administration'. Together they form a unique fingerprint.

Cite this